Alice Melão, MSc,  —

Verona Pharma’s investigational agent RPL554 will be named ensifentrine, the company announced. The “-fentrine” stem in the International Nonproprietary Names (INN) Programme indicates recognition from the World Health Organization (WHO) that RPL554 inhibits multiple phosphodiesterases. Ensifentrine is being developed for the maintenance treatment of chronic obstructive pulmonary disease (COPD)…

Theravance Biopharma and Mylan announced that the U.S. Food and Drug Administration (FDA) approved their New Drug Application (NDA) for revefenacin (TD-4208) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The therapy will be marketed as an inhalation solution with the brand name Yupelri. The…

A fully functional 3D-printed artificial lung may someday help people with serious pulmonary illnesses, such as chronic obstructive pulmonary disease (COPD). A Department of Veterans Affairs (VA) research team, in collaboration with Old World Labs — a company in Hampton, Virginia, specializing in high-resolution 3D printing — is working to…

The addition of Verona Pharma’s investigational agent RPL554 to standard short- and long-acting bronchodilators offers greater clinical benefits to patients with chronic obstructive pulmonary disease (COPD). Results of two Phase 2 clinical trials (NCT02542254 and NCT03028142) demonstrated that the RPL554 add-on could enhance the bronchodilation action…

AstraZeneca’s Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) has been shown to have similar therapeutic activity in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) as GlaxoSmithKline’s approved therapy Anoro Elipta (umeclidinium/vilanterol). Bevespi Aerosphere combines a fixed dose of two bronchodilators — glycopyrrolate, a…

Psychological distress, even at low or moderate levels, increases the risk of arthritis, cardiovascular disease, and chronic obstructive pulmonary disease (COPD), researchers have found. This finding was reported in the study, “The effects of psychological distress and its interaction with socioeconomic position on risk of developing…

A new clinical trial being conducted in the United Kingdom is recruiting participants to study the early stages of chronic obstructive pulmonary disease (COPD), and identify people at risk of developing the disease. This will be the first study to track changes in lung function over time before COPD…

Preliminary results from a Phase 2 trial show that Synairgen’s investigative therapy SNG001 is well-tolerated by patients with chronic obstructive pulmonary disease (COPD). The ongoing two-part Phase 2 trial, called SG015 (2017-003679-75), is evaluating the safety and effectiveness of SNG001 to prevent acute worsening of COPD symptoms…

The investigational monoclonal antibody Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), top-line results of the Phase 3 TERRANOVA trial have shown. The disappointing results follow previously announced data from the Phase 3 GALATHEA trial that also showed the candidate…

AB569, Arch Biopartners’ lead therapy candidate, has received a U.S. patent for the treatment of chronic lung infections in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis. Patent 9,925,206 was issued by the U.S. Patent and Trademark Office to the University of Cincinnati, which previously granted…